Table 4 Incidence of treatment-related adverse events at 96-week pooled from HAWK and HARRIER [Source: [16]]
Adverse event | Brolucizumab 6 mg (n = 730) | Aflibercept 2 mg (n = 729) | ||||
|---|---|---|---|---|---|---|
Number of patients with AEs (N) | Incidence (%) | SE | Number of patients with AEs (N) | Incidence (%) | SE | |
Cataract | 2 | 0.15% | 0.14% | 1 | 0.07% | 0.10% |
Endophthalmitis | 4 | 0.30% | 0.2% | 1 | 0.07% | 0.10% |
Intraocular inflammation | 6 | 0.45% | 0.2% | 0 | 0.00% | 0.00% |
Detachment of the retina | 2 | 0.15% | 0.1% | 2 | 0.15% | 0.14% |
Retinal pigment epithelial tear | 2 | 0.15% | 0.1% | 0 | 0.00% | 0.00% |
Retinal tear | 2 | 0.15% | 0.1% | 1 | 0.07% | 0.10% |